Detalhe da pesquisa
1.
A prospective, multicenter study on hematopoietic stem-cell mobilization with cyclophosphamide plus granulocyte colony-stimulating factor and 'on-demand' plerixafor in multiple myeloma patients treated with novel agents.
Haematologica;
2023 Nov 16.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37981892
2.
Carfilzomib combined with lenalidomide and dexamethasone (KRd) as salvage therapy for multiple myeloma patients: italian, multicenter, retrospective clinical experience with 600 cases outside of controlled clinical trials.
Hematol Oncol;
40(5): 1009-1019, 2022 Dec.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35638723
3.
Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma patients.
Eur J Haematol;
108(3): 178-189, 2022 Mar.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34716957
4.
Efficacy and safety of once-weekly bortezomib in multiple myeloma patients.
Blood;
116(23): 4745-53, 2010 Dec 02.
Artigo
em Inglês
| MEDLINE
| ID: mdl-20807892
5.
Melphalan 200 mg/m(2) versus melphalan 100 mg/m(2) in newly diagnosed myeloma patients: a prospective, multicenter phase 3 study.
Blood;
115(10): 1873-9, 2010 Mar 11.
Artigo
em Inglês
| MEDLINE
| ID: mdl-19965659
6.
Survival Risk Scores for Real-Life Relapsed/Refractory Multiple Myeloma Patients Receiving Elotuzumab or Carfilzomib In Combination With Lenalidomide and Dexamethasone as Salvage Therapy: Analysis of 919 Cases Outside Clinical Trials.
Front Oncol;
12: 890376, 2022.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35924160
7.
Daratumumab as Single Agent in Relapsed/Refractory Myeloma Patients: A Retrospective Real-Life Survey.
Front Oncol;
11: 624405, 2021.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33763359
8.
Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label study.
Lancet Haematol;
7(12): e861-e873, 2020 Dec.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33242443
9.
Lenalidomide Maintenance with or without Prednisone in Newly Diagnosed Myeloma Patients: A Pooled Analysis.
Cancers (Basel);
11(11)2019 Nov 05.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31694338
10.
Feasibility, Tolerability and Efficacy of Carfilzomib in Combination with Lenalidomide and Dexamethasone in Relapsed Refractory Myeloma Patients: A Retrospective Real-Life Survey of the Sicilian Myeloma Network.
J Clin Med;
8(6)2019 Jun 19.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31248142
11.
Maintenance in myeloma patients achieving complete response after upfront therapy: a pooled analysis.
J Cancer Res Clin Oncol;
144(7): 1357-1366, 2018 Jul.
Artigo
em Inglês
| MEDLINE
| ID: mdl-29675792
12.
Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial.
Lancet;
367(9513): 825-31, 2006 Mar 11.
Artigo
em Inglês
| MEDLINE
| ID: mdl-16530576
13.
The genetic and genomic background of multiple myeloma patients achieving complete response after induction therapy with bortezomib, thalidomide and dexamethasone (VTD).
Oncotarget;
7(9): 9666-79, 2016 Mar 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-26575327
14.
Lenograstim reduces the incidence of febrile episodes, when compared with filgrastim, in multiple myeloma patients undergoing stem cell mobilization.
Leuk Res;
35(7): 899-903, 2011 Jul.
Artigo
em Inglês
| MEDLINE
| ID: mdl-21134693
15.
Absolute lymphocyte count is unrelated to overall survival in newly diagnosed elderly patients with multiple myeloma treated with immunomodulatory drugs.
Leuk Lymphoma;
56(5): 1507-9, 2015 May.
Artigo
em Inglês
| MEDLINE
| ID: mdl-25139690
16.
Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma.
J Clin Oncol;
28(12): 2077-84, 2010 Apr 20.
Artigo
em Inglês
| MEDLINE
| ID: mdl-20308672
17.
Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma.
Blood;
109(7): 2767-72, 2007 Apr 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-17148584
18.
Oral melphalan, prednisone, and thalidomide for newly diagnosed patients with myeloma.
Cancer;
104(7): 1428-33, 2005 Oct 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-16116606
19.
All-trans retinoic acid induced cardiac and skeletal myositis in induction therapy of acute promyelocytic leukaemia.
Br J Haematol;
129(3): 444-5, 2005 May.
Artigo
em Inglês
| MEDLINE
| ID: mdl-15842672